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Abstract
Background: Rare variants have gathered increasing attention as a possible alternative source of missing heritability.
Since next generation sequencing technology is not yet cost-effective for large-scale genomic studies, a widely used
alternative approach is imputation. However, the imputation approach may be limited by the low accuracy of the
imputed rare variants. To improve imputation accuracy of rare variants, various approaches have been suggested,
including increasing the sample size of the reference panel, using sequencing data from study-specific samples (i.e.,
specific populations), and using local reference panels by genotyping or sequencing a subset of study samples. While
these approaches mainly utilize reference panels, imputation accuracy of rare variants can also be increased by using
exome chips containing rare variants. The exome chip contains 250 K rare variants selected from the discovered
variants of about 12,000 sequenced samples. If exome chip data are available for previously genotyped samples, the
combined approach using a genotype panel of merged data, including exome chips and SNP chips, should increase
the imputation accuracy of rare variants.
Results: In this study, we describe a combined imputation which uses both exome chip and SNP chip data
simultaneously as a genotype panel. The effectiveness and performance of the combined approach was
demonstrated using a reference panel of 848 samples constructed using exome sequencing data from the
T2D-GENES consortium and 5,349 sample genotype panels consisting of an exome chip and SNP chip. As a
result, the combined approach increased imputation quality up to 11 %, and genomic coverage for rare variants up to
117.7 % (MAF < 1 %), compared to imputation using the SNP chip alone. Also, we investigated the systematic
effect of reference panels on imputation quality using five reference panels and three genotype panels. The
best performing approach was the combination of the study specific reference panel and the genotype panel
of combined data.
Conclusions: Our study demonstrates that combined datasets, including SNP chips and exome chips, enhances both
the imputation quality and genomic coverage of rare variants.
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Background
Genome-wide association studies (GWAS) have revealed
unprecedented numbers of disease-associated loci [1, 2].
However, previously reported loci explain only a small
proportion of heritability [2–4]. Previous GWAS mainly
focused on common variants that was readily accessible
via initial genomic technologies [2]. Through recent ad-
vancements in high-throughput sequencing technology,
more complete genome-wide assessment of variants has
become possible [5]. Recent large scale sequencing studies
reported that the population frequencies of a large propor-
tion of discovered variants were rare (Minor Allele
Frequency (MAF) < 1 %) [6–8]. Given their abundance,
rare variants have been increasingly recognized as an
alternative source of missing heritability [5, 7, 9]. However,
large-scale, population-based genomic sequencing studies
are not yet feasible, due to high cost and computation-
intensive analysis [10, 11].
Alternatively, imputation has been widely used for
studying rare variants. Imputation has estimated untyped
rare variants using thousands of sequenced samples avail-
able as a reference panel such as the 1,000 genomes
project data [12, 13]. Recent imputation-based association
studies have revealed numerous uncommon or rare vari-
ants associated with coronary artery disease, blood cell
traits, serum creatinine, chronic kidney disease, and adult
body height [10, 12, 13]. However, imputing rare variants
has been challenging, due to the low accuracy of imputed
genotypes of rare variants [10, 14], and poorly imputed
rare variants may mislead follow-up association studies.
Imputation requires a reference panel and genotype
panels. The reference panel is the basis for imputation
performance, and the genotype panel is made from ob-
served data. From both the reference and genotype panels,
the shared haplotype segments are estimated using vari-
ants present on both panels. Then, the untyped genotypes
are imputed using these haplotypes [15]. The accuracy of
imputation can be increased by improving the reference
panel and the genotype panel.
Previously, numerous studies have reported enhanced
imputation performance of rare variants [14, 16–19],
using three types of basic approaches for improving refer-
ence panels. The first is to increase the number of samples
of the reference panel [14]. The second approach uses a
study-specific reference panel instead of a public reference
panel (e.g., the 1,000 genomes project reference panel)
[16, 17]. The last ‘two step approach’ uses a local reference
panel consisting of a subset of samples with a chip con-
taining many low frequency variants or local sequencing
data [18, 19]. Such local reference panels are used to com-
plement public reference panels. These three approaches
mainly focus on improving the reference panels by con-
structing an independent, study-specific reference panel,
or complementing an existing public reference panel.
Alternatively, the imputation accuracy of rare variants
can also be increased by improving a genotype panel
using a chip designed to contain rare variants or
markers tagging nearby rare variants [14, 18]. For ex-
ample, an exome chip is a customized chip containing
about 250 K variants including rare functional coding
variants selected from ~ 12,000 sequenced samples [20]
that can be genotyped at less cost than commercial
genome-wide single nucleotide polymorphism (SNP)
chips containing rare variants. While exome chips
alone were shown as insufficient for imputation, as
compared to commercial SNP chips widely used for
GWAS [21], exome chips additionally genotyped for
previously SNP chip-genotyped samples would improve
their utility as a good source of rare variants. Moreover,
a genotype panel combining exome chips and SNP chip
data can help construct population-specific haplotypes
carrying rare variants, thus also increasing the imputation
accuracy of rare variants.
In this study, we propose a new strategy to increase
the accuracy of imputation of rare variants by improving
a new genotype panel by combining exome chip with
existing SNP chip data. We show that the new genotype
panel of combined data of exome chip and SNP chip im-
proves imputation quality of imputed rare variants. To
demonstrate the effectiveness of our strategy for improv-
ing genotype panels, we compared imputation strategies
based on three genotype panels: 1) exome chip only; 2)
SNP chip only; and 3) combined SNP chip and exome
chip. Performances were compared via imputation qual-
ity scores [22] and genomic coverages [23, 24].
We also performed a systematic investigation of the ef-
fect of the reference panel on the imputation quality of rare
variants. Using 848 samples with whole exome sequencing
data (WES), SNP chip data (GWAS), and exome chip data
(EXOME), we built various reference panels: WES +
GWAS+ EXOME, WES +GWAS, WES + EXOME, WES,
and the 1000 genomes phase 1 dataset (1KG). We then
performed imputation on 5,349 samples with three geno-
type panels of exome chip, SNP chip, and combined data.
Additionally, to assess the effect of the reference panel
sample size on imputation performance, we varied the
number of samples from 300 to 848, by increments of 200,
to examine the performance of imputation strategies.
Results
Exclusion of poorly-imputable variants
In this study, we used the estimated r2 ( r^ 2 ) values pro-
vided by the imputation software minimac [15, 25] as im-
putation quality scores. The r^ 2 is an estimate of the true
r2 (dosage r2), which is the squared correlation of the true
genotypes and imputed genotypes [25]. It is given by com-
paring the variance of imputed genotype scores with the
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variance of expected genotype scores. Previously, Li et al.
reported that r^ 2 was poorly estimated for very rare vari-
ants (MAF ≤ 0.5 %) [14]. Almost all variants with poorly
calibrated r^ 2 were very rare variants. Also, the Pearson
correlation coefficient between r^ 2 and dosage r2 was
below 0.9 (0.783–0.825) for very rare variants, but it was
more than 0.9 (0.951–0.983) for variants with MAF >
0.5 % [14]. If the r^ 2 could not estimate the true value
closely, then our comparative analysis of imputation per-
formance would yield misleading results. In this context,
we called very rare variants as “poorly-imputable variants”
if the Pearson correlation coefficient r^ 2 and dosage r2 was
below 0.9 and excluded them for further analysis.
We compared r^ 2 and dosage r2 in four different MAF
bins. We divided the variants into four MAF bins based on
MAF: common (MAF ≥ 5 %), less common (MAF 1–5 %),
rare (MAF 0.5–1 %), and very rare (MAF < 0.5 %) [14]. To
measure the strength of the linear relationship between
r^ 2 and dosage r2, Pearson correlation coefficients were
calculated for each MAF bin. We first performed im-
putation on the genotype panel containing the SNP
chip only by using our WES + GWAS + EXOME refer-
ence panel. Among imputed variants, 45,802 variants
from 5,349 samples were compared to the correspond-
ing variants obtained from an exome chip constructed
using identical samples. Figure 1 shows the imputation
results of variants by MAF bins. The Pearson correl-
ation coefficients were 0.98, 0.97, 0.94, and 0.77 for
MAF bins ≥5 %, 1–5 %, 0.5–1 %, and < 0.5 %, respect-
ively. As Li et al. reported, r^ 2 did not reflect the true
value, dosage r2, for very rare variants (MAF < 0.5 %,
Fig. 1d). However, r^ 2 became closer to the dosage r2, as
the MAF increased (Fig. 1a–c).
In this study, we used whole exome sequencing data
(~18,000 genes) for studying imputation performance.
However, Li et al. studied imputation performance using
sequencing data of only 202 genes [14]. Since the results
may be different depending on the data, we thoroughly
analyzed very rare variants to study the lower bound of al-
lele frequency showing good estimation of dosage r2. Very
rare variants were split into discrete MAF bins of width
0.001. The Pearson correlation coefficients were 0.91, 0.90,
0.87, 0.78, and 0.55 for MAF bins 0.4–0.5 %, 0.3–0.4 %,
0.2–0.3 %, 0.1–0.2 %, and 0–0.1 %, respectively. The
Pearson correlation coefficients were 0.98, 0.97, 0.94,
0.77 for MAF bins ≥ 5 %, 1–5 %, 0.5-1 %, and < 0.5 %,
respectively. Among very rare variants, MAF bins with
MAF < 0.3 % showed that the Pearson correlation coeffi-
cients dropped below 0.9 (Fig. 1e–f ). If these variants are
included in the analysis, poorly estimated r^ 2 may cause
Fig. 1 Scatter plot of estimated r2 against dosage r2 by MAF bins. Estimated r2 was plotted against dosage r2 by MAF bins (a) MAF≥ 5 %, (b)
MAF = 1–5 %, (c) MAF = 0.5–1 %, (d) MAF < 0.5 %, (e) MAF = 0.3–0.5 %, and (f) MAF < 0.3 %. The red dotted line represents the diagonal
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less consistent results to those using dosage r2. There-
fore, the variants with MAF < 0.3 % (369,309 of 856,690
variants) were regarded as poorly-imputable and excluded
from further study.
Comparison of imputation quality among genotype
panels
Using the WES + GWAS + EXOME reference panel ex-
cluding poorly imputable variants, we performed imput-
ation on three genotype panels, including exome chip
only, SNP chip only, and combined data of exome chip
and SNP chip. For the purpose of comparison, we selected
108,682 imputed variants overlapping the three genotype
panels. The r^ 2 value was used to measure imputation
quality. The numbers of variants were 35,443 (32.6 %),
21,191 (19.5 %), 19,527 (18.0 %), and 32,547 (29.9 %) for
variants with MAF ≥ 5 %, 1−5 %, 0.5−1 %, and < 0.5 %, re-
spectively. Figure 2 shows the comparison results. As pre-
viously reported, the genotype panel of the exome chip
alone showed the worst performance [21]. The mean r^ 2
values were 0.332, 0.616, and 0.661 for the genotype
panels of exome chip, SNP chip, and combined ap-
proach, respectively. Thus, the combined genotype
panel showed the best performance compared to the
other genotype panels (Wilcoxon signed rank sum
test P-values < 2.2x10−16, a 7.3 % relative increase in
the mean of the r^ 2 compared to those of SNP chip
only). In Fig. 2, most imputed variants using the
combined approach performed better than the geno-
type panel of SNP chip alone. The mean values of the r^ 2
of SNP and combined approach were 0.870 and 0.906 for
MAF ≥ 5 %, 0.653 and 0.706 for MAF 1−5 %, 0.465 and
0.515 for MAF 0.5−1 %, and 0.406 and 0.452 for
MAF <0.5 %, respectively. The relative increment in r^ 2
of the combined genotype panel was 4.1 % for common
variants (MAF ≥ 5 %), 8.1 % for less common variants
(MAF 1−5 %), 10.7 % for rare variants (MAF 0.5−1 %),
and 11.4 % for very rare variants (MAF < 0.5 %), com-
pared to the genotype panel with SNP chip only. Thus,
the increment in imputation quality was largest when
the minor allele frequencies of the imputed variants
were below 1 %.
Comparison of genomic coverage among genotype
panels
We next compared the genotype panels in terms of their
genomic coverage, i.e., the proportion of variants captured
by a genotyping chip [24]. The larger the genomic cover-
age, the better the association mapping performance. One
major advantage of imputation lies in obtaining a large
dense set of imputed variants from a relatively small num-
ber of observed variants on the genotype panel. These im-
puted variants enhanced genomic coverage, resulting in
increased association power [15], enabling us to perform in
silico fine mapping in imputation-based association studies.
Likewise, Nelson et al. recently reported imputation-based
genomic coverage of widely used genotyping chips [24].
Imputation-based genomic coverage is calculated as the
number of imputed variants with quality scores above the
threshold value (info score ≥ 0.8) divided by the total num-
ber of variants in the reference panel [24].
In this study, we compared imputation-based genomic
coverage of three genotype panels. We imputed genotype
panels using the WES+GWAS + EXOME reference panel.
For genomic coverage, we selected 143,022 exonic vari-
ants, including those imputed and genotyped by exome
chip. Since we used exome sequencing data to construct
the reference panel, 143,022 variants were regarded as a
“virtual” exome. The numbers of variants were 56,326
(39.4 %), 28,072 (19.6 %), 22,931 (16.0 %), and 35,693
(25.0 %) with MAFs ≥ 5 %, 1−5 %, 0.5−1 %, and < 0.5 %, re-
spectively. Table 1 summarizes the genomic coverages. We
also selected two cut-off values for r^ 2 : 0.8 as a stringent
cut-off, and 0.4 as a less stringent cut-off. This 0.8 stringent
cut-off provided a genomic coverage of 0.435 for the SNP
chip only and 0.560 for the combined approach, respect-
ively, while the less stringent cut-off ( r^ 2 ≥ 0.4) provided
genomic coverages of 0.749 and 0.818 for SNP chip only
and the combined approach, respectively. Overall, the
combined approach yielded approximately 9.2 % (r^ 2 ≥ 0.4)
and 29 % (r^ 2≥ 0.8) relative increases in genomic coverage
of all variants. However, for rare variants (MAF < 1 %) ap-
plying stringent cut-offs ( r^ 2 ≥ 0.8), the genomic coverage
of the combined approach increased by 98.6 % and
117.7 %, compared to that of the SNP chip only, for
Fig. 2 Mean estimated r2 of genotype panels by MAF bins
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variants with MAFs of 0.5–1 % and < 0.5 %, respectively.
Thus, the combined approach greatly improved genomic
coverages of rare variants.
Systematic effect of various reference panels on
imputation quality
Systematic analysis of reference panels could establish an
effective strategy for improving imputation quality of rare
variants. We first investigated systematically the effects of
various reference panels on imputation quality using five
different reference panels, including 1KG, WES, WES +
EXOME, WES +GWAS, and WES +GWAS+ EXOME.
We then compared imputation qualities by using 15 pos-
sible combinations of three genotype panels and five refer-
ence panels. r^ 2 values were used to measure imputation
quality. For comparisons, we selected 66,920 variants im-
puted by all 15 combinations. Figure 3 shows the imput-
ation qualities by genotype panels used: Fig. 3a for exome
chip, 3b for SNP chip, and 3c for the combined. Imput-
ation quality was influenced by reference panels, and the
same reference panel showed different imputation quality
when used for imputing different genotype panels. The
WES + EXOME reference panel was the best performing
genotype panel of exome chips, and the WES +GWAS +
EXOME reference panel was best for the genotype panels
of SNP chip and the combined data. The 1KG reference
panel was the worst performing genotype panel of exome
chip, and the WES reference panel for the genotype panels
of SNP chip and the combined data.
We next investigated why imputation quality differed
across the reference panels, and found two factors: 1) dif-
ferences in the number of overlapping variants between
the reference and genotype panels; and 2) shared haplo-
type patterns between the reference and genotype panels.
First, overlapping variants between the reference and
genotype panels play important roles in imputation. For
predicting untyped genotypes, imputation uses estimated
haplotype segments from the reference panel for the
overlapping variants between reference and genotype
panels. The lower the number of overlapping variants
between the reference and genotype panels, the worse
the imputation quality, due to inaccurate estimation of
haplotype segments. The numbers of overlapping variants
are summarized in Table 2. For study-specific reference
panels that included WES data, the worst performing
reference panel had the smallest number of overlapping
variants, while the best performing reference panel had
the most overlapping variants. This is the reason why
the best and worst performing reference panels were
different according to the genotype panels used. For ex-
ample, WES + EXOME reference panel showed the best
performance for the genotype panel of exome chip
(Fig. 3a). The number of overlapped variants was 38,243,
Table 1 Genomic coverage of genotype panels of SNP chip only and combined approach
MAF
bin
Estimated r2 ≥ 0.8 Estimated r2 ≥ 0.4
Exome chip SNP chip Combined Exome chip SNP chip Combined
ALL 0.367 0.435 0.560 0.492 0.749 0.818
≥5 % 0.600 0.794 0.901 0.756 0.953 0.983
1–5 % 0.374 0.403 0.588 0.510 0.799 0.881
0.5–1 % 0.192 0.146 0.290 0.290 0.585 0.686
<0.5 % 0.107 0.079 0.172 0.192 0.491 0.591
Fig. 3 Mean estimated r2 of various combinations of reference panels and genotype panels. Reference panels are the 1000 genomes phase 1
dataset (1KG) and various combinations of whole exome sequencing data (WES), SNP chip data (GWAS), and exome chip data (EXOME)
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which was the largest number among the number of over-
lapping variants between the four study-specific reference
panels and genotype panel of exome chip (Table 2). On
the other hand, WES + EXOME was the 2rd worst per-
forming for other genotype panel, having the 2nd smallest
number of overlapping variants (Figs. 3a and 3b, Table 2).
Second, the use of shared haplotype patterns between
the reference and genotype panels also improved the ac-
curacy of imputation. Although the 1KG reference panel
had the largest number of overlapped variants, its imput-
ation quality was worse than using study-specific refer-
ence panels such as WES + EXOME for exome chip
(Fig. 3a) and WES + GWAS + EXOME for the genotype
panels of SNP chip and the combined data (Fig. 3b and
3c). As previously reported [17], the better performance
of study-specific reference panels over 1KG was due to
more shared haplotype segments between study-specific
reference panels and the genotype panels used [17, 26].
All samples of study-specific reference panels and geno-
type panels were from a Korean population, whereas the
1KG reference panel consists of samples from various
populations such as Europeans, Africans, and Asians.
Thus, the 1KG reference panel and the genotype panel
of Korean population do not have many shared haplo-
types, resulting in poor imputation.
Comparative analysis of the 15 different combinations
provided us effective imputation strategies for imputing
rare variants when a specific genotype panel is given
with a specific reference panel. For example, compared
to the case of the SNP chip genotype panel with the
1KG reference panel, three strategies could increase the
imputation quality of rare variants: 1) use the best per-
forming reference panel, e.g., WES + GWAS + EXOME,
instead of 1KG; 2) construct the genotype panels of
combined data by additional genotyping of an exome
chip for those samples already genotyped using the SNP
chip; and 3) use the genotype panel of combined data
from (2, above) with WES + GWAS + EXOME as a refer-
ence panel. The first strategy increased imputation qual-
ity from 0.445 to 0.622 for rare variants and from 0.377
to 0.553 for very rare variants. When the second strategy
was applied, the imputation quality was 0.503 and 0.426
for rare and very rare variants, while the best performing
strategy was the third, increasing imputation quality to
0.664 and 0.595 for rare and very rare variants,
respectively.
Sample size effect of reference panel on imputation
quality
It was previously shown that the larger the sample size
of the reference panel, the better the imputation qual-
ity [14]. Here, we systematically investigated the effect
of sample size on imputation quality. Since the WES +
GWAS + EXOME reference panel performed the best,
we studied the sample size effect of WES + GWAS +
EXOME reference panel on imputation quality. We
performed imputation on the genotype panels of SNP
chip and combined data with reference sample sizes of
300, 500, 700, and 848. This analysis was restricted to
variants on chromosome 1, to focus only on overlap-
ping imputed variants. The total number of imputed
variants used for this analysis was 10,624. Figure 4
shows the mean r^ 2 of SNP chip only and combined
data by different sample sizes for the reference panel.
As expected, imputation quality increased as the sam-
ple size of reference panel increased.
For the imputed rare variants (MAF 0.5–1 %) using
the combined data genotype panel, relative increases in
mean r^ 2 values were 8.2 % and 4.5 % for increasing the
reference panel sample size from 300 to 500, and 500 to
700, respectively (Table 3), and 0.93 % for sample size
increases from 700 to 848. Increments in mean r^ 2 values
were the lowest between 700 and 848 samples used for
the reference panel. Therefore, increasing the sample size
to more than 700 would not be cost-effective for improv-
ing imputation quality of rare variants. Similarly, imput-
ation qualities of very rare variants (MAF <0.5 %) showed
similar patterns to those of rare variants. When we per-
formed the same analysis for the SNP chip genotype panel,
Table 2 The number of overlapped variants between reference
panels and genotype panels
Reference panels Exome chip SNP chip Combined
WES 21,120 4,472 24,514
WES + EXOME 38,243 7,323 41,637
WES + GWAS 23,972 344,359 364,402
WES + GWAS + EXOME 38,243 344,359 378,695
1KG 49,286 344,359 389,715
Fig. 4 Mean estimated r2 varied by sample size of reference panel
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similar patterns were observed for both rare and very rare
variants.
This study of sample size also provided us cost-effective
sample size determination strategies for imputing rare var-
iants. Instead of constructing a reference panel with a
large number of samples, it would be more cost-effective
to combine the reference panel with a smaller number of
samples and the genotype panel of combined data. Table 4
(MAF 0.5–1 %) summarizes the relative increases in im-
putation quality. For example, the genotype panel of com-
bined data with 500 samples of reference panel showed
better imputation quality (mean r^ 2 = 0.510) than the
genotype panel of SNP chip only data with 848 samples of
reference panel (mean r^ 2 = 0.498) (Fig. 4).
Discussion
In this study, we proposed a new strategy for increasing
imputation quality of rare variants, i.e., a combined ap-
proach that uses the genotype panel of combined data
including SNP chip and exome chip for imputation.
Using a WES +GWAS + EXOME reference panel, we
showed that the genotype panel of combined data yielded
better imputation quality than other genotype panels. For
rare variants (MAF < 1 %), the combined approach rela-
tively increased imputation quality up to 11 % and en-
hanced genomic coverage up to 117.7 %, as compared to
the genotype panel of SNP chip only.
In addition, we systematically investigated the effect of
various reference panels on imputation quality. We believe
the current study is the first to systematically analyze im-
putation qualities by combining various reference panels
and genotype panels. The best imputation quality for rare
variants was obtained using the study-specific reference
panel WES +GWAS + EXOME and the genotype panel of
combined data.
Our study also provides a guideline for researchers to
establish more cost-effective imputation strategies for
increasing the imputation quality of rare variants. As
shown in the results, combining a reference panel with a
reasonable sample size and the combined data genotype
panel is a cost-effective approach to increasing imput-
ation quality of rare variants. For example, we reported
that the genotype panel of combined data with 500 sam-
ples of reference panel outperformed the genotype panel
of SNP chip with 848 samples of reference panel. The
cost per sample of exome sequencing ($750) is about 11
times more expensive than those of exome chip ($70)
[27]. If less than 3,700 samples were genotyped, generat-
ing exome chip data would be much more cost-effective
than producing additional 348 samples of exome se-
quencing data. As an alternative to producing exome
sequencing data or genotyping exome chip data, the
merged panel approach which combine the concaten-
ation of a public reference panel (e.g. 1,000 genomes
project data) and a study specific reference panel, can
be considered to increase the sample size of reference
panel. Recent studies reported that the merged panel
enhanced imputation performance [17, 28]. Also,
1,000 genomes project phase 3 data became available,
providing 2,504 samples of whole genome sequencing
data [29]. Since rare variants tend to be population
specific [30], the merged panel approach would be ef-
fective if study samples were closely related with pop-
ulations of 1KG data. Populations of 1KG phase 3 are
African (661 samples), American (347 samples), East
Asian (504 samples), European (503 samples), and
South Asian (489 samples). Customized genotyping
chip can also be an alternative approach if none of
SNP chip and exome chip data is available. Consider-
ing the frequency of rare variant in a specific popula-
tion, one can design a study specific genotyping chip
containing rare variants. For example, UK biobank de-
signed a chip containing 821 K SNPs [31]. Among
them, about 111 K variants were rare coding variants
(see url: http://www.ukbiobank.ac.uk/scientists-3/uk-
biobank-axiom-array/). Therefore, based on our re-
sults, a rare variant association research considering
the study data and populations of study samples can
be designed more cost-effectively.
Despite providing a new imputation strategy and valuable
insights for imputing rare variants, the current study has
several limitations that should be noted. First, we removed
substantial amount of variants from our analysis. Poorly-
imputable variants (MAF < 0.3 %) were 43.1 % of variants
in the initial reference panel. If additional true genotype
Table 3 Relative increase in mean estimated r2 by reference
sample size (MAF 0.5–1 %)
Genotype panel 300 to 500 500 to 700 700 to 848
SNP chip only 9.27 % 4.90 % 2.09 %
Combined (SNP + exome chip) 8.18 % 4.46 % 1.74 %
Table 4 Relative increase in mean estimated r2 by using
combination of reference panel and combined approach
(MAFs 0.5–1 %)
R300-C R500-C R700-C R848-C
R300-G 10.88 % 19.95 % 25.30 % 27.49 %
R500-G 1.47 % 9.77 % 14.67 % 16.67 %
R700-G −3.27 % 4.64 % 9.31 % 11.21 %
R848-G −5.25 % 2.50 % 7.07 % 8.94 %
The names of panels were abbreviated as follows: R (reference panel),
G (the genotype panel of SNP chip only), and C (the genotype panel of
combined data). R300, R500, R700, and R848 indicates sample sizes of 300, 500,
700, and 848 for reference panel, respectively. R(sample size) -G represents
combination of R(sample size) reference panel and G genotype panel.
R(sample size)-C represents the combination of R(sample size) reference
panel and C genotype panel
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data is available (e.g. exome sequencing data), dosage r2
can be calculated instead of estimated r2, then thorough
analysis would be possible for all very rare variants. Second,
the case samples of the reference panel may influence im-
putation results. Generally, public reference panels are
consists of normal samples [8]. In this study, the 848 sam-
ples of the reference panel are consists of 415 type 2 dia-
betes and 433 controls. To analyze the impact of samples
with disease status in the reference panel on imputation
performance, we performed imputation on chromosome 1
of combined genotype panel using the reference panel con-
sisting of 415 cases and the reference panel consisting of
433 controls. After that, we calculated the Pearson correl-
ation coefficient between imputation qualities of two refer-
ence panels. The Pearson correlation coefficient was 0.96.
Also Duan et al. previously reported that there was no loss
of imputation quality using the reference panel consisting
of samples with phenotypic extremes or disease status [17].
Thus, imputation results of our study may not be influ-
enced by cases of the reference panel. Third, the compari-
son analysis of this study may not be exhaustive. We
compared the imputation performance of the reference
panels; however, 1KG phase 3 data and the merged panel
approach were not included in the analysis. Further study
is warranted to compare the reference panels and related
approaches exhaustively. Lastly, our study did not report
explicit cost benefits by imputation strategies considering
costs of bioinformatics and whole genome sequencing. In
practice, sequencing data analysis and imputation are not
free of charge in considering compute-intensive analysis.
Therefore, explicit cost-benefits analyses that argue for op-
timal designs in light of difference cost structures are re-
quired for a further study.
Next generation sequencing (NGS) provides base-pair
resolution data and generated a near complete cata-
logue of genetic variants in human genome [8]. Unlike
previous genome studies that focused on using initial
genomic technologies such as chip-based genotyping
on common variants, NGS is expected to uncover the
role of less common and rare variants in various
diseases. However, due to high cost and computation-
intensive analysis, large-scale, population based gen-
omic sequencing studies are not yet feasible [10, 11].
Although NGS is not yet cost-effective for large-scale
genome studies, it will soon become essential, as its
cost rapidly decreases. Meanwhile, imputation-based
research strategies would be cost-effective for identify-
ing associations between diseases and variants, includ-
ing less common and rare variants.
Conclusions
Here, we proposed a combined approach that imputes
rare variants using the genotype panel of combined data
including SNP chip and exome chip. We evaluated the
performance of the combined approach using 848 sam-
ples from a study-specific reference panel and 5,349
samples of genotype panels consisting of exome chips
only, SNP chips only, and combined data from an exome
chip and a SNP chip. For rare variants (MAF < 1 %), the
combined approach greatly increased imputation quality
approximately 11 % compared to that of the exome chip
only and showed up to a 117.7 % increase in genomic
coverage. The proposed combined approach would be a
cost-effective strategy to obtain better imputation quality
and enhanced genomic coverage for rare variants.
We also systematically investigated the effect of various
combinations of reference panels and genotype panels.
The best performing approach combined data from a
study-specific reference panel and a genotype panel.
Methods
Study samples
As part of the Korean Genome Analysis Project, Korea
Association REsource (KARE) study was initiated in
2007 to conduct a large-scale genome-wide association
study aiming to discover variants associated with Type
2 diabetes and numerous complex traits. The detailed
information has been described elsewhere [32]. Briefly,
a total of 10,038 participants aged 40 to 69 were re-
cruited from two population-based cohorts comprising
the Ansung (n = 5,018) and Ansan (5,020) cohorts. In
this study, we used exome sequencing data and geno-
typing data from KARE samples. All participants of
KARE provided written informed consent. The study
using KARE samples was approved by two independent
institutional review boards at Seoul National University
and the National Institute of Health, Korea.
Exome sequencing
By the Type 2 Diabetes Genetic Exploration by Next-
generation Sequencing in Ethnic Samples (T2D-GENES)
Consortium, about 10,000 exomes from five ethnic
groups were sequenced using Agilent Human Exon v2
capture (~18,000 genes) at the Broad Sequencing Center.
Among these, part of the samples are from the KARE
project [32], including unrelated 538 type 2 diabetes
samples and 579 control samples, were included, and
1,087 samples were used for further analysis after sample
quality control. The reference genome hg19 was used
for alignment and variant calling performed using the
Genome Analysis Toolkit v2 [33]. Among 1,087 exome
sequenced samples, only 848 samples had data of both
SNP chip and exome chip. As a result, 500,821 auto-
somal variants from 848 Korean samples were used for
constructing reference panels. The accuracy of the called
variants was calculated by comparing genotypes from se-
quencing data with genotypes of genotyping chip data,
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showing overall concordances of 99.76 % and 99.96 %
for the Affymetrix 5.0 and exome chips, respectively.
SNP chip and exome chip data
Previously, 8,842 samples of KARE project were genotyped
using the Affymetrix Genome-Wide Human SNP Array
5.0 (Affymetrix Inc., San Diego, CA, USA) [32]. Among
them, 6,197 identical samples were genotyped using the
Illumina HumanExome BeadChip v1.1 (Illumina, Inc., San
Diego, CA, USA) exome chip. For the two platforms,
standard sample quality controls were conducted, ex-
cluding those with a high missing rate (>4 %), gender
discrepancy, excessive heterozygosity, or cryptic first-
degree relatives. Exclusion criteria for the Affymetrix SNP
chip were: Hardy-Weinberg equilibrium p-values < 10−6,
genotype call rates < 95 %, and MAF < 0.01. All SNP
chromosomal positions were updated to hg19 using the
Affymetrix annotation file. Quality control of exome chip
variants was similar to that of the SNP chip, except for the
threshold for filtering out variants with low allele fre-
quency. Only monomorphic variants were excluded for
further analysis. From quality controlled data, we used
6,197 samples that were common between sets of the
Affymetrix SNP chip and exome chips. Variants in-
cluded in the analysis were 344,366, and 66,196 for
the SNP chip and exome chip, respectively. Among
6,197 samples, 848 samples were used for construct-
ing the reference panel, and the remaining 5,349 sam-
ples were used for genotype panels.
Construction of reference panels
We constructed the reference panel by merging whole
exome sequencing, exome chip, and SNP chip of 848
identical samples. Prior to merging, overlapping variants
between the WES and chip data were removed from
chip datasets. For overlapping variants between GWAS
and EXOME, variants from EXOME were used to re-
move overlapping variants from GWAS. After merging
all the data, the initial reference panel contained 856,690
variants. For comparisons, we excluded poorly imputable
variants (MAFs < 0.3 %) for further analysis. The final
WES +GWAS + EXOME reference panel contained
487,381 variants and was phased using the ShapeIT v2
program [34]. After phasing, a subset of variants from the
WES + GWAS + EXOME reference panel was selected
for constructing three reference panels: WES, WES +
GWAS, and WES + EXOME. We also downloaded
1,000 genomes phase I Shapeit2 reference with no
monomorphic and no singleton sites from MACH website
(http://www.sph.umich.edu/csg/abecasis/MACH).
Construction of genotype panels
Among 6,197 samples, 5,349 samples remained after ex-
cluding 848 samples were used for constructing the
reference panel. The genotype panel consisting of exome
chip of 5,349 samples was phased using the ShapeIT v2
progam. As the genotype panel of SNP chip only, SNP
chip data of 5,349 samples were phased using the ShapeIT
v2 program. For the genotype panel of combined data, the
SNP chip and exome chip of 5,349 identical samples were
merged and phased using the ShapeIT v2 program.
Statistical analysis
In this study, we performed typical pre-phasing-based
imputation on genotype panels [35]. For imputation, we
used minimac software, a low memory and computa-
tionally efficient implementation of the MaCH algorithm
[25]. The dosage r2 was accessed by calculating squared
Pearson correlations between imputed dosages and true
genotypes from exome chip. For comparison analysis of
imputation performance, we used r^ 2 provided by mini-
mac as an imputation quality measure. To compare the
imputation results between pairs of genotype panels,
Wilcoxon signed-rank tests were performed for r^ 2
values of imputed variants. Statistical analyses and
visualization of the results were performed using the R
program (http://www.r-project.org).
Availability of data
Exome sequencing data will be available on dbGAP. The
genotype data of KARE samples are available by sending
a request to the Distribution desk of Korea Biobank
Network, National Institute of Health, Korea.
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